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Abstract
Background—Review of the historical growth in annual vaccination coverage across countries 
and regions can better inform decision makers’ development of future goals and strategies to 
improve routine vaccination services.
Methods—Using the World Health Organization (WHO) and the United Nations Children's Fund 
estimates of annual national third dose of diphtheria-tetanus-pertussis–containing vaccine (DTP3) 
and third dose of polio vaccine (POL3) coverage for 1980–2009, we calculated the mean absolute 
annual rate of change in national DTP3 coverage among all countries (globally) and among 
countries within each WHO region, as well as the number of years taken by each region to reach 
specific regional coverage levels. Last, we assessed differences in mean absolute annual rate of 
change in DTP3 coverage, stratified by baseline level of DTP3 coverage.
Results—During the 1980s, global DTP3 coverage increased a mean of 5.3 percentage points/
year. Annual rate of change decreased to 0.5 percentage points/year in the 1990s and then 
increased to 0.9 percentage points/year during the 2000s. Mean annual rate of change in coverage 
across all countries was highest (9.2 percentage points) when national coverage levels were 26%–
30% and lowest (−0.9 percentage points) when national coverage levels were 96%–100%. 
Regional differences existed as both WHO South-East Asia Region and WHO African Region 
countries experienced mean negative DTP3 coverage growth at lower coverage levels (81%–85%) 
than other regions. The regions that have achieved 95% DTP3 coverage (Americas, Western 
Pacific, and European) took 25–29 years to reach that level from a level of 50% DTP3 coverage. 
POL3 coverage change trends were similar to described DTP3 coverage change trends.
Conclusions—Mean national coverage growth patterns across all regions are nonlinear as 
coverage levels increase. Saturation points of mean 0 percentage-point growth in annual coverage 
varies by region and require further investigation. The achievement of >90% routine coverage is 
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observed to take decades, which has implications for disease eradication and elimination 
initiatives.
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The Expanded Program on Immunization (EPI) began in 1974 with the goal of ensuring that 
all children benefit from life-saving vaccines [1]. Vaccination coverage is a key indicator of 
vaccination program performance, and coverage for the third dose of diphtheria-tetanus-
pertussis–containing vaccine (DTP3) is often used as the main indicator for performance of 
routine vaccination services. Strong routine vaccination services, as measured by high DTP3 
vaccination coverage, are critical for successful implementation of key global public health 
goals. For instance, strong routine vaccination is one of the 4 core strategies for reaching and 
sustaining polio eradication in the 2010–2012 strategic plan of the Global Polio Eradication 
Initiative (GPEI) [2, 3]. By 2009, global DTP3 coverage reached 83%, indicating the 
commitment by many countries to reduce mortality and morbidity from vaccine-preventable 
diseases (VPD).
In 2000, the World Health Organization (WHO) and the United Nations Children's Fund 
(UNICEF) began a process of annually estimating global, regional, and national routine 
vaccination coverage across multiple vaccines, including DTP vaccine, polio vaccine (POL), 
and measles-containing vaccine (MCV). These estimates, which are updated annually, are 
based on officially reported data from government administrative sources, coverage surveys, 
and other published and unpublished work [4]. WHO and UNICEF also undertook a 
retrospective review of these sources to estimate vaccination coverage for 1980–1999. These 
estimates are used for a wide variety of reasons, including global pay-for-performance 
incentives, tracking the attainment of key child survival goals, and immunization program 
objectives and estimates of general changes in infant and child mortality [5–8]. Although 
these estimates are generally considered the most reliable source of coverage, concerns have 
been raised about the accuracy of the administrative sources used in the estimates, compared 
with coverage survey sources [9].
These vaccination coverage estimates provide an opportunity to assess the historical 
performance of national and regional vaccination services. Generally, analyses of program 
performance are limited to a brief synopsis of changes in coverage since the previous year 
[10]. However, benefits exist in an in-depth analysis of the historical performance of 
vaccination programs worldwide, including how vaccination coverage has varied over time, 
how varying levels of coverage affect annual changes in coverage, and how coverage has 
varied between different geographical regions. Such analysis would be informative for the 
further development of polio, measles, and other vaccine-preventable disease elimination 
and eradication goals, routine vaccination performance goals, and the application of routine 
vaccination strategies based on the existing level of performance of a country's vaccination 
program. Specifically, the 2013–2018 Polio Eradication and Endgame Strategic Plan 
includes the strengthening of immunization systems as one of 4 objectives to boost 
immunity and help wide-scale introduction of inactivated polio vaccine (IPV) [10]. The 
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main indicator of this objective is achievement of a ≥10% annual increase in DTP3 coverage 
in 80% of high-risk districts of key polio-focus countries between 2014 and 2018 [11].
We studied 1980–2009 vaccination coverage data and assessed (1) the annual mean rate of 
change in vaccination coverage for countries in each geographic region, (2) the number of 
years needed to reach various coverage levels by each region, and (3) variability in the 




National DTP3 coverage levels jointly estimated by the WHO and UNICEF were used to 
calculate the annual rate of change in annual coverage from 1980 to 2009 [12]. The WHO 
and UNICEF jointly define DTP3 coverage as the number of children who receive DTP3 by 
12 months of age, divided by the estimated number of children surviving to their first 
birthday [4]. Regional and global coverage estimates are calculated using population-
weighted national coverage from all countries in a given region or globally; national 
population data were sourced from WHO/UNICEF immunization reports [13].
For geographical categorization of countries, we used WHO's classification of WHO 
member states: African Region, Eastern Mediterranean Region, European Region, Region of 
the Americas, South-East Asia Region, and Western Pacific Region [14].
Analysis of Global and Regional Annual Rate of Change in Coverage
We examined global, regional, and country absolute annual rates of change in DTP3 
coverage, the third dose of POL (POL3), and the first dose of measles-containing vaccine 
(MCV1). We calculated the annual rate of change in coverage for each country by 
subtracting the country's vaccination coverage for the year from its coverage during the 
preceding year to calculate an absolute rate of annual change. We calculated the mean 
annual rate of change in a region's coverage by averaging the calculated annual absolute rate 
of change in coverage across all countries within a given region for a given year. To account 
for potential irregularities in the annual rate due to occurrence of single-year extremes, we 
averaged the annual rate of change for each region's countries during 3 periods: 1980–1989, 
1990–1999, and 2000–2009.
Analysis of Annual Rate of Change in Coverage by Baseline Vaccination Coverage Level
We examined the absolute annual rate of change in coverage at different baseline coverage 
levels and compared these rates at high baseline coverage levels with those at low levels. To 
do so, we first created 5 percentage-point-increment baseline coverage categories, ranging 
from 1%–5% through 96%–100%. We then calculated the absolute change in coverage for 
each year by subtracting national vaccination coverage for the year from the national 
coverage during the preceding year. For example, if DTP3 coverage for a country was 71% 
in 2007 and 77% in 2008, the absolute annual rate of change would be 6 percentage points 
([coverage in year 2008] – [coverage in year 2007]). This absolute annual rate of change 
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was associated with a baseline coverage level category of 71%–75% because the baseline 
year (ie, 2007) coverage was 71%. We calculated regional, population-weighted means for 
the absolute annual rate, using values from the countries in each region, and calculated 
global, population-weighted averages, using all countries in the WHO/UNICEF joint 
estimates data set. To further illustrate the speed and level of the annual rate of change in 
coverage per baseline coverage category, we calculated a cumulative change in coverage. 
The latter indicator was calculated by cumulatively summing a region's mean absolute 
annual rate of change in coverage as the baseline coverage level increased. For example, if a 
region's mean absolute annual rate of change for the 1%–5% baseline coverage category was 
5 percentage points and the mean absolute annual rate of change for the 6%–10% baseline 
coverage category was 4 percentage points, the cumulative change in coverage at the 10% 
baseline coverage level was 9 percentage points.
Analysis of Number of Years for Regions to Reach Specific Coverage Levels
We examined the number of years it took for each region to reach specific DTP3, POL3, and 
MCV1 coverage levels (ie, 60%, 70%, 80%, 90%, and 95%) from a coverage level of 50%. 
The number of years was calculated by determining which year a region's coverage first 
reached or went above a specific coverage level and subtracting that year from the year 
when the region initially passed a previous specific coverage level.
RESULTS
Global, Regional, and National Rates of Change in DTP3 Coverage
Globally, coverage increased from 1980 to 2009, but the annual rate of change slowed over 
time and varied between regions. From 1980 through 2009, global DTP3 coverage increased 
from 20% to 82%; however, coverage levels varied substantially among WHO regions 
(Figure 1). While DTP3 coverage in the Region of the Americas, the European Region, and 
the Western Pacific Region exceeded 90% in 2009, it was 71% in the African Region and 
73% in the South-East Asia Region.
During the same period, global DTP3 coverage increased by 2.1 percentage points annually 
(Table 1). However, coverage slowed over time as the greatest mean annual change in 
global DTP3 coverage occurred in the 1980s (5.3 percentage points/year) and then slowed 
dramatically during the 1990s (0.5 percentage points/year) and 2000s (0.9 percentage points/
year). The latter 2 decades correspond to periods of higher vaccination coverage levels; for 
example, during the 2000s, mean global DTP3 coverage was 78%.
When we analyzed POL3 and MCV1 coverage, similar trends as those observed for DTP3 
coverage during 1980–2009 were found (Figure 1 and Figure 3). In the analysis of the 
change in regional coverage during 1980–2009, the mean change in MCV coverage was 0.1 
percentage point higher than the mean change in DTP3 across regions. During the same 
period, the mean annual change in global POL3 coverage was equal to the corresponding 
change for DTP3 (Table 1).
Certain countries lagged behind others in coverage levels and in both direction and speed of 
the annual change in coverage. At the national level, by 2009, 122 of 193 countries (63%) 
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had ≥90% DTP3 coverage, and 186 countries (96%) had a positive mean annual change in 
DTP3 coverage during 1980–2009. A minority of countries (14%) experienced both <90% 
DTP3 coverage in 2009 and either a negative or 0 percentage point mean annual change in 
DTP3 coverage during 1999–2009 (Figure 2).
DTP3 Annual Rate of Coverage Change, by Baseline Level of DTP3 Coverage
The direction and speed of the annual rate of change in coverage in a country or region 
differed depending on the level of its baseline vaccination coverage. Generally, the mean 
annual rate of change was greatest when coverage was low; conversely, the mean annual 
rate of change slowed at higher coverage levels. At baseline DTP3 coverage levels of ≤5%, 
the mean annual rate of change in DTP3 coverage the following year across all countries 
was 2.1 percentage points (Figure 3). Mean annual rate of change in coverage continued to 
increase as coverage increased from 5% up to 26%–30%. The highest mean annual rate of 
change in DTP3 coverage was 9.2 percentage points; this occurred when DTP3 coverage 
was 26%–30%. At higher DTP3 coverage levels, the mean annual increase in DTP3 
coverage slowed to between 1 and 6 percentage points at coverage levels of 41%–80% and 
was <1 percentage point when coverage was 81%–90%. At coverage levels of >90%, the 
mean annual rate of change in coverage was negative.
We found a similar pattern in the mean annual rate of change in DTP3 coverage at different 
coverage levels across WHO regions (Figure 4). In most regions, the annual rate of change 
in DTP3 coverage started low (<5 percentage points/year) when baseline coverage was 
<10%, and the annual rate of change was greatest when coverage was approximately 30%. 
The rate of change in coverage then generally declined toward 0 percentage points as 
coverage approached 100%; in some regions, annual rate of change became negative when 
coverage exceeded 80%.
Although the general trend patterns were similar among the regions, there were some 
important differences, including the maximum mean annual rate of change in DTP3 
coverage achieved and the coverage levels at which the mean annual rate of change became 
negative. For countries in the Eastern Mediterranean Region, the South-East Asian Region, 
the African Region, and the Western Pacific Region, the mean annual rate of change in 
DTP3 coverage was <3 percentage points when DTP3 coverage was 1%–5%. Mean rate of 
change in DTP3 coverage increased at higher coverage levels, peaked when coverage was 
16%–30%, and declined as coverage increased further (Figure 4). At high (>80%) levels of 
coverage in these regions, mean annual rate of change in coverage was minimal (<1 
percentage point) and eventually became negative in all regions. In both the Region of the 
Americas and the European Region, the annual rate of change in coverage did not become 
negative until DTP3 coverage exceeded 95%, whereas in the African Region and the South-
East Asia regions, this occurred at DTP3 coverage levels as low as 81%–85%. The mean 
annual rate of change in coverage at any coverage level was generally lower in the African 
Region than in other regions. Both MCV1 and POL3 annual rates of change in coverage, 
stratified by coverage level, followed similar patterns to those described previously for 
DTP3 (Figure 3).
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Years to Reach Coverage Levels at the Regional Level
The number of years that elapsed until vaccination coverage increased from a level of 50% 
to higher levels varied by region (Table 2). For example, in the Region of the Americas, it 
took 8 years for regional DTP3 coverage to increase from 50% to 70%, an additional 3 years 
to increase from 70% to 80%, and 18 more years to reach 95%. The European Region 
followed a similar pattern as the Region of the Americas, whereas the Western Pacific 
Region's pattern differed in requiring a short, 3-year period to increase from 70% to 90% but 
20 years to reach 95%. Of the 3 regions that have achieved 95% DTP3 coverage (the Region 
of the Americas, the European Region, and the Western Pacific Region) and the 2 regions 
that have achieved 95% POL3 coverage, >20 years were needed to increase coverage from 
50% to 95%. No region has yet achieved 95% MCV1 coverage.
DISCUSSION
Although the duration needed to increase vaccination coverage among countries in each 
region varies substantially, the general nonlinear pattern of mean annual rate of change in 
coverage is similar. Temporally, the highest mean annual rate of change in coverage for 
MCV, DTP, and POL were measured during the 1980s. From a perspective of coverage 
levels, the highest mean annual rate of change in coverage occurred when national coverage 
levels were approximately 25%–30%. For coverage levels between 30% and 80%, mean 
annual rate of change in coverage generally decreased toward 0 percentage points and 
became negative as coverage levels reached 90%–95%. The results indicate difficulty in 
maintaining positive annual growth in vaccination coverage at levels above 90%. This 
threshold point of 0 or negative rates of change in coverage differed between regions’ 
countries. Only 3 regions reached >95% DTP3 coverage, 2 regions reached >95% POL3 
coverage, and no regions reached >95% MCV1 coverage. Regions that have reached 95% 
coverage required an average of 25.2 years to increase coverage from 50% to >95%.
Our analysis’ observed nonlinear growth curve for vaccination coverage is similar to rates of 
change described for other public health interventions [15]. The nonlinear pattern can be 
roughly described as an s-shaped trajectory in which little growth occurs at the lowest levels 
of coverage, followed by rapid growth as coverage begins to increase, and then an eventual 
leveling off of coverage as coverage stabilizes. In 1981, Shuval et al proposed the threshold 
saturation theory to describe the factors that help explain the shape of this type of growth 
curve within the context of water and sanitation interventions [15]. The theory states when 
health status related to the intervention is poor, it is indicative of few, if any, investments in 
the public health intervention. As investments increase, at some point a threshold is passed 
and intervention coverage growth rapidly occurs and, consequently, health status rapidly 
improves. However, health status and intervention coverage eventually stop growing as they 
reach a saturation point, at which time additional investments both internal and external to 
the health intervention may be required to further improve health status. In relation to our 
analysis, a key finding is how this saturation point for vaccination program coverage differs 
by region and may be indicative of the differing levels of investment across regions. These 
investment differences take the form of differences in availability of human resources for 
health, number of health facilities, and related infrastructure and ability to absorb external 
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investments in health [16–19].Future regional comparisons should focus on identifying the 
factors underlying these differences in saturation points between regions.
The observed growth curve in vaccination coverage may also indicate a need to evolve 
program objectives and performance indicators as coverage increases. For instance, when 
vaccination coverage is low, general access to vaccination services is a challenge, so 
investments should focus on establishing vaccine supply chains and ensuring adequate 
numbers of vaccinators and service delivery points. Key performance indicators during this 
period may be national vaccination coverage across antigens. When the rate of change in 
vaccination coverage begins to slow, efforts should be made to identify subnational (ie, 
region and district) areas where coverage is low, because their performance is masked by 
high national coverage yet also causes national coverage growth to slow [20]. Program 
improvement strategies can also shift toward subnational approaches, such as the Reaching 
Every District strategy [21]. As vaccination coverage improves, inclusion of other 
performance indicators, such as timeliness of vaccination, may also be needed to ensure that 
a complete picture of program performance is available [20].
Strong performance in the African Region is critical to lowering VPD mortality and 
reaching disease eradication goals. Therefore, our analyses may be useful in establishing a 
projection of future African Region performance. One way to do this is to use another 
region's performance as a basis. The current state of the African Region bears similarities to 
that of the Region of the Americas in the past, and consequently, the historical performance 
of the Region of the Americas may serve as a best-case example of how quickly 
immunization goals could be achieved in the African Region. Both regions contain many 
countries (>40), and when the EPI began, many countries in the Region of the Americas 
were low income, similar to the current state of many countries in the African Region. In 
2009, the African Region's DTP3 coverage was 71%. When DTP3 coverage in the Region 
of the Americas was 70%, in the 1980s, it took 11 years to achieve the GIVS immunization 
coverage goal of 90%. Similarly, it took the European Region 16 years to achieve this goal. 
A second projection method is to use the African Region's current DTP3 coverage growth 
trends (1.8 percentage points/year during the last decade). On the basis of this method, it 
will take 11 years for the African Region to reach 90% coverage. These methods provide a 
range of 11 to 16 years for the region to reach 90% DTP3 coverage; however, the 
investments needed to sustain positive growth will likely need to match or exceed 
investments seen in the other regions to do so, particularly if the rest of these African 
countries’ socioeconomic indicators do not improve at rates similar to those observed in 
these other regions.
This analysis is subject to certain limitations. First, it relies on a mix of administrative data, 
survey data, and interpretation of these data by the WHO and UNICEF. Although the WHO/
UNICEF estimates are generally considered the best vaccination estimates for a country, 
administrative estimates have been shown to be substantially higher than those obtained by 
surveys [9]. Our analysis is ecological in nature, but the consistency of trends within and 
across regions suggests that these patterns exist irrespective of other confounding factors.
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VPD elimination and eradication initiatives, including the GPEI, emphasize low routine 
coverage levels as a key barrier to the success of disease eradication and elimination and 
VPD mortality reductions [22, 23]. These initiatives do emphasize investments in routine 
vaccination alongside other strategies to reach disease elimination and eradication goals. 
The longevity of these strategies and investments to increase immunization coverage should 
fit in with realistic expectations of what can be achieved within a certain time line. 
Consideration should be given to the results presented here and to the GPEI indicator of a 
10% annual increase in 80% of the high-risk districts in key GPEI countries from 2014 to 
2018 [11]. Realistic time lines based on what other countries have already achieved may 
also serve to further motivate key stakeholders to achieve these same goals. Fortunately, 
investment for immunization programs has increased substantially since the early years of 
the EPI in the 1980s [24, 25]. For example, since 2000, multiple new global immunization 
initiatives, including the GAVI Alliance, the Measles and Rubella Initiative, and the Global 
Vaccine Action Plan 2010–2020, have brought substantial resources to support and 
strengthen immunization services and health systems and have committed countries to 
provide further investments through mechanisms, such as cofinancing [26, 27]. However, 
backers of these initiatives should understand that the historical trends in routine 
immunization coverage indicate that annual rates of change in coverage are neither fast nor 
reliably positive. Therefore, lasting investments in strategies with long-term goals and 
objectives are needed to achieve the societal benefits of strengthening routine immunization 
programs worldwide, including the eradication of polio and the elimination and control of 
other vaccine-preventable diseases.
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Global and regional vaccination coverage from 1980 to 2009, based on World Health 
Organization (WHO)/United Nations Children's Fund coverage estimates [12]. Region 
definitions are based on WHO categorization [14]. Abbreviations: DTP3, third dose of 
diphtheria-tetanus-pertussis–containing vaccine; MCV1, first dose of measles-containing 
vaccine; POL3, third dose of polio vaccine.
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National coverage with a third dose of diphtheria-tetanus-pertussis–containing vaccine 
(DTP3) during 2009 and absolute annual rate of change in national DTP3 coverage during 
1999–2009. Each dot represents 1 country; the size of the dot is defined by the number of 
unvaccinated children in the country as of 2009, based on World Health Organization 
(WHO)/United Nations Children's Fund DTP3 coverage estimates and United Nations 
population estimates [12, 13]. GIVS, Global Immunization Vision and Strategy Framework 
for 2006 to 2015 (used as a global framework of goals and objectives for vaccination 
programs worldwide, including the GIVS 2015 national coverage goals of 90%).
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Mean and cumulative absolute annual rates of change in global vaccination coverage, by 
coverage category, 1980–2009. Data are based on World Health Organization/United 
Nations Children's Fund coverage estimates [12]. DTP3, third dose of diphtheria-tetanus-
pertussis–containing vaccine; MCV, measles-containing vaccine; POL3, third dose of polio 
vaccine.
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Mean and cumulative absolute annual rates of change in regional coverage by the third dose 
of diphtheria-tetanus-pertussis–containing vaccine (DTP3) per coverage category, 1980–
2009. Data are based on World Health Organization (WHO)/United Nations Children's Fund 
coverage estimates [12]. Regions and countries are defined according to WHO standards 
[14].
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Table 2
Times From 50% to 60%–95% Vaccination Coverage During 1980–2009, by World Health Organization 
(WHO) Region, 1980–2009
Time, y, by Final Coverage Level
Region, Vaccine 60% 70% 80% 90% 95%
African Region
    DTP3 15 18 NR NR NR
    MCV 16 NR NR NR NR
    POL3 13 18 NR NR NR
Region of the Americas
    DTP3 3 8 11 19 29
    MCV 4 8 10 17 NR
    POL3 NA 4 8 19 NR
Eastern Mediterranean Region
    DTP3 1 3 18 NR NR
    MCV 2 12 19 NR NR
    POL3 2 4 19 NR NR
European Region
    DTP3 NA 1 11 17 25
    MCV NA 3 9 19 NR
    POL3 NA NA 4 16 21
South-East Asia Region
    DTP3 NA 1 NR NR NR
    MCV NA 3 5 NR NR
    POL3 1 5 NR NR NR
Western Pacific Region
    DTP3 1 2 5 5 25
    MCV NA 3 9 10 NR
    POL3 NA NA 3 6 26
Data are based on WHO/United Nations Children's Fund coverage estimates [12].
Abbreviations: DTP3, third dose of diphtheria-tetanus-pertussis–containing vaccine; MCV, measles-containing vaccine; NA, not applicable 
(starting coverage was already above the given level); NR, not reached (the given level has not yet been reached); POL3, third dose of polio 
vaccine.
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